**Supplementary Fig. 14. Forest plot of adverse events with SOF/VEL + RBV for the treatment of patients with decompensated hepatitis C cirrhosis.** The AE associated with treatment increased when RBV was added to SOF/VEL: 91.1% (95% CI: 85.4–95.6) vs. 50.2% (95% CI: 18.9–81.4), *p*=0.0077). SOF, sofosbuvir; VEL, velpatasvir; RBV, ribavirin; AE, adverse events.

